Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
16.12
+0.12 (0.75%)
At close: Aug 14, 2026, 4:00 PM EDT
15.80
-0.32 (-1.99%)
After-hours: Aug 14, 2026, 7:56 PM EDT
Janux Therapeutics Employees
Janux Therapeutics had 113 employees as of June 30, 2026. The number of employees increased by 10 or 9.71% compared to the same quarter last year.
Employees
113
Change
10
Growth
9.71%
Revenue / Employee
$212,389
Profits / Employee
-$907,894
Market Cap
985.52M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 113 | 10 | 9.71% |
| Mar 31, 2026 | 108 | 17 | 18.68% |
| Dec 31, 2025 | 109 | 28 | 34.57% |
| Sep 30, 2025 | 109 | 33 | 43.42% |
| Jun 30, 2025 | 103 | 34 | 49.28% |
| Mar 31, 2025 | 91 | 23 | 33.82% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 12 | 18.75% |
| Jun 30, 2024 | 69 | 2 | 2.99% |
| Mar 31, 2024 | 68 | 6 | 9.68% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Sep 30, 2023 | 64 | 8 | 14.29% |
| Jun 30, 2023 | 67 | 18 | 36.73% |
| Mar 31, 2023 | 62 | 21 | 51.22% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Sep 30, 2022 | 56 | 28 | 100.00% |
| Jun 30, 2022 | 49 | 27 | 122.73% |
| Mar 31, 2022 | 41 | 25 | 156.25% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Kura Oncology | 260 |
| Geron | 258 |
| Olema Pharmaceuticals | 150 |
| Solid Biosciences | 121 |
| Odyssey Therapeutics | 100 |
| Annexon | 92 |
| Lexicon Pharmaceuticals | 81 |
JANX News
- 9 days ago - Janux Therapeutics price target lowered to $35 from $38 at Stifel - TheFly
- 9 days ago - Janux Therapeutics price target lowered to $55 from $58 at Guggenheim - TheFly
- 9 days ago - Janux Therapeutics reports Q2 EPS (35c), consensus (29c) - TheFly
- 9 days ago - Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - Business Wire
- 10 days ago - Janux Therapeutics Quarterly report: Q2 2026 - Filings
- 10 days ago - Janux Therapeutics Earnings release: Q2 2026 - Filings
- 7 weeks ago - Janux Therapeutics assumed with a Buy at Truist - TheFly
- 7 weeks ago - Janux Therapeutics reports departure of Chief Medical Officer - TheFly